BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-silberstein F. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J Antimicrob Chemother 2016;71:739-50. [DOI: 10.1093/jac/dkv403] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Brancaccio G, Sorbo MC, Frigeri F, Rizzo V, Cantone M, Genderini F, Fabeni L, Pinto A, Perno CF, Ceccherini-Silberstein F, Gaeta GB. Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy. Clin Gastroenterol Hepatol 2018;16:977-8. [PMID: 29104131 DOI: 10.1016/j.cgh.2017.10.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
2 Jiang X, Lv X, Chang L, Yan Y, Ji H, Sun H, Guo F, Rodgers MA, Yin P, Wang L. Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors. Antiviral Res 2020;181:104871. [PMID: 32717286 DOI: 10.1016/j.antiviral.2020.104871] [Reference Citation Analysis]
3 Minosse C, Gruber CEM, Rueca M, Taibi C, Zaccarelli M, Grilli E, Montalbano M, Capobianchi MR, Antinori A, D'Offizi G, McPhee F, Garbuglia AR. Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs. Viruses 2021;13:1151. [PMID: 34208646 DOI: 10.3390/v13061151] [Reference Citation Analysis]
4 Loggi E, Vukotic R, Conti F, Gitto S, Andreone P. Gold standard assays for the monitoring of patients with chronic hepatitis C. Future Virology 2018;13:529-37. [DOI: 10.2217/fvl-2018-0032] [Reference Citation Analysis]
5 Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxì A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. Liver Int 2021;41:1802-14. [PMID: 33497016 DOI: 10.1111/liv.14797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Mansoor S, Javed A, Ali A, Mansoor A. Heterogeneous genomic locations within NS3, NS4A and NS4B identified for genotyping and subtyping of Hepatitis C virus: A simple genome analysis approach. Infection, Genetics and Evolution 2016;44:61-8. [DOI: 10.1016/j.meegid.2016.06.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
7 Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017;37:514-528. [PMID: 28105744 DOI: 10.1111/liv.13327] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 11.2] [Reference Citation Analysis]
8 Cuypers L, Thijssen M, Shakibzadeh A, Sabahi F, Ravanshad M, Pourkarim MR. Next-generation sequencing for the clinical management of hepatitis C virus infections: does one test fits all purposes? Crit Rev Clin Lab Sci 2019;56:420-34. [PMID: 31317801 DOI: 10.1080/10408363.2019.1637394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Marascio N, Pavia G, Strazzulla A, Dierckx T, Cuypers L, Vrancken B, Barreca GS, Mirante T, Malanga D, Oliveira DM, Vandamme AM, Torti C, Liberto MC, Focà A; The SINERGIE-UMG Study Group. Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients. Int J Mol Sci 2016;17:E1416. [PMID: 27618896 DOI: 10.3390/ijms17091416] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
10 Bruzzone B, Magnani O, Sticchi L, Canepa P, Rappazzo E, Icardi G, Setti M. Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy. J Antimicrob Chemother 2017;72:2955-8. [PMID: 29091216 DOI: 10.1093/jac/dkx222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Bruzzone B, Canepa P, De Rosa G, Delucis S, D'Ambrosio B, Icardi G, Setti M. Correct Identification of Dual HCV Infections in HIV/HCV CoInfected Patients. AIDS Res Hum Retroviruses 2018;34:325-6. [PMID: 29314861 DOI: 10.1089/aid.2017.0133] [Reference Citation Analysis]
12 Tavares RCF, Feldner ACCA, Pinho JRR, Uehara SNO, Emori CT, Carvalho-Filho RJ, Silva ISS, Santana RAF, de Castro VFD, Castoli GTF, Cristovão CU, Ferraz MLCG. Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection. Eur J Gastroenterol Hepatol 2017;29:754-8. [PMID: 28234637 DOI: 10.1097/MEG.0000000000000866] [Reference Citation Analysis]